Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | SETD2 | Q9BYW2 | 2/20 | 0.58 |
| ▸ | BRAF | P15056 | 1/20 | 0.56 |
| ▸ | KMO | O15229 | 1/20 | 0.56 |
| ▸ | CASP3 | P42574 | 1/20 | 0.56 |
| ▸ | CASP7 | P55210 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | PRKDC | P78527 | 2/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30577363 | 1.00 | JAK2 (0.61) | JAK2POLBMEN1KMT2AMAPT | |
| SCHEMBL16583818 | 0.87 | KMO (0.61) | POLBMEN1KMT2AMAPTKDM4E | |
| SCHEMBL10473262 | 0.86 | MAPT (0.66) | JAK2POLBMEN1KMT2AMAPT | |
| SCHEMBL3496105 | 0.85 | KMO (0.56) | POLBMEN1KMT2AMAPTKDM4E | |
| SCHEMBL5801780 | 0.85 | CYP1A2 (0.67) | JAK2POLBMEN1KMT2AMAPT | |
| SCHEMBL10396194 | 0.85 | POLB (0.56) | POLBMEN1KMT2AMAPTRAB9A | |
| SCHEMBL30577378 | 0.84 | HTR1D (0.60) | ALDH1A1SETD2CASP3CASP7GAA | |
| SCHEMBL429085 | 0.83 | MAPT (0.75) | JAK2POLBMEN1KMT2AMAPT | |
| SCHEMBL1383637 | 0.82 | GAA (0.56) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL6424561 | 0.82 | KMO (0.63) | POLBMAPTRAB9AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1581467-B1 | LIGANDS FOR METALS AND IMPROVED METAL-CATALYZED PROCESSES BASED THEREON | MASSACHUSETTS INST TECHNOLOGY (US) | 2016-10-12 | — | — | EP | disclosed |
| EP-1581467-B1 | LIGANDS FOR METALS AND IMPROVED METAL-CATALYZED PROCESSES BASED THEREON | MASSACHUSETTS INST TECHNOLOGY (US) | 2016-10-12 | — | — | EP | disclosed |
| EP-2583958-B1 | Ligands for metals and improved metal-catalyzed processes based thereon | MASSACHUSETTS INST TECHNOLOGY (US) | 2016-08-10 | — | — | EP | disclosed |
| EP-2583958-B1 | Ligands for metals and improved metal-catalyzed processes based thereon | MASSACHUSETTS INST TECHNOLOGY (US) | 2016-08-10 | — | — | EP | disclosed |
| US-9346799-B2 | Useful combinations of monobactam antibiotics with beta-lactamase inhibitors | BASILEA PHARMACEUTICALS AG (CH) | 2016-05-24 | — | — | US | disclosed |
| US-20160122320-A1 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2016-05-05 | — | — | US | disclosed |
| US-20150031662-A1 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2015-01-29 | — | — | US | disclosed |
| US-8901293-B2 | Useful combinations of monobactam antibiotics with beta-lactamase inhibitors | BASILEA PHARMACEUTICA AG (CH) | 2014-12-02 | — | — | US | disclosed |
| US-8901293-B2 | Useful combinations of monobactam antibiotics with beta-lactamase inhibitors | BASILEA PHARMACEUTICA AG (CH) | 2014-12-02 | — | — | US | disclosed |
| EP-2484680-B1 | Useful Combinations of Monobactam Antibiotics with beta-Lac-tamase Inhibitors | BASILEA PHARMACEUTICA AG (CH) | 2013-06-26 | — | — | EP | disclosed |
| EP-1581467-A4 | LIGANDS FOR METALS AND IMPROVED METAL-CATALYZED PROCESSES BASED THEREON | MASSACHUSETTS INST TECHNOLOGY (US) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007065288-A2 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2007-06-14 | — | — | WO | disclosed |
| US-7223879-B2 | Ligands for metals and improved metal-catalyzed processes based thereon | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223879-B2 | Ligands for metals and improved metal-catalyzed processes based thereon | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223879-B2 | Ligands for metals and improved metal-catalyzed processes based thereon | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2007-05-29 | — | — | US | disclosed |
| CN-1745049-A | Ligands for metals and improved metal-catalyzed processes based thereon | MASSACHUSETTS INST TECHNOLOGY (US) | 2006-03-08 | — | — | CN | disclosed |
| EP-1581467-A2 | LIGANDS FOR METALS AND IMPROVED METAL-CATALYZED PROCESSES BASED THEREON | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2005-10-05 | — | — | EP | disclosed |
| US-20040171833-A1 | Ligands for metals and improved metal-catalyzed processes based thereon | NATIONAL SCIENCE FOUNDATION | 2004-09-02 | — | — | US | disclosed |
| WO-2004052939-A2 | LIGANDS FOR METALS AND IMPROVED METAL-CATALYZED PROCESSES BASED THEREON | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2004-06-24 | — | — | WO | disclosed |
| US-4923974-A | COLORFASTNESS, BRIGHTNESS, BUILD-UP | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1990-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031662-A1 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | MGAM, MGAM2, B2M | JAK2 3978/4885POLB 316/4885MEN1 2778/4885 |
| US-20040171833-A1 | Ligands for metals and improved metal-catalyzed processes based thereon | THEM6, SLC30A6, SOD1 | JAK2 2062/4885POLB 2411/4885MEN1 1463/4885 |
| US-20160122320-A1 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | MGAM, MGAM2, B2M | JAK2 3978/4885POLB 316/4885MEN1 2778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.